Ultimovacs Management
Management criteria checks 3/4
Ultimovacs' CEO is Carlos de Sousa, appointed in Jun 2020, has a tenure of 4.25 years. total yearly compensation is NOK6.50M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth NOK58.89K. The average tenure of the management team and the board of directors is 4.3 years and 9.7 years respectively.
Key information
Carlos de Sousa
Chief executive officer
NOK 6.5m
Total compensation
| CEO salary percentage | 74.5% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.3yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -NOK 179m |
| Mar 31 2024 | n/a | n/a | -NOK 178m |
| Dec 31 2023 | NOK 7m | NOK 5m | -NOK 189m |
| Sep 30 2023 | n/a | n/a | -NOK 204m |
| Jun 30 2023 | n/a | n/a | -NOK 186m |
| Mar 31 2023 | n/a | n/a | -NOK 165m |
| Dec 31 2022 | NOK 8m | NOK 5m | -NOK 168m |
| Sep 30 2022 | n/a | n/a | -NOK 148m |
| Jun 30 2022 | n/a | n/a | -NOK 153m |
| Mar 31 2022 | n/a | n/a | -NOK 168m |
| Dec 31 2021 | n/a | n/a | -NOK 165m |
| Sep 30 2021 | n/a | n/a | -NOK 138m |
| Jun 30 2021 | n/a | n/a | -NOK 126m |
| Mar 31 2021 | n/a | n/a | -NOK 124m |
| Dec 31 2020 | NOK 5m | NOK 3m | -NOK 121m |
Compensation vs Market: Carlos's total compensation ($USD606.75K) is above average for companies of similar size in the UK market ($USD365.10K).
Compensation vs Earnings: Carlos's compensation has been consistent with company performance over the past year.
CEO
Carlos de Sousa (66 yo)
4.3yrs
Tenure
NOK 6,504,000
Compensation
Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.3yrs | NOK 6.50m | 0.076% NOK 58.9k | |
| Chief Financial Officer | 8.8yrs | NOK 4.41m | 0.17% NOK 129.3k | |
| Head of Research | no data | NOK 2.57m | no data | |
| Chief Technology Officer | 3.6yrs | NOK 2.92m | no data | |
| Chief Medical Officer | 8.3yrs | NOK 4.29m | no data | |
| Head of Clinical Operations | 7.1yrs | NOK 2.71m | no data | |
| Chief Business Officer | 3.8yrs | NOK 4.43m | 0.0032% NOK 2.5k | |
| Head of Regulatory Affairs & QA | 2.9yrs | NOK 2.37m | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Head of Office | no data | no data | no data |
4.3yrs
Average Tenure
Experienced Management: ULTIO's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Board member | no data | NOK 250.00k | no data | |
| Independent Chairman | 13.7yrs | NOK 450.00k | 0.015% NOK 12.0k | |
| Independent Director | 5.7yrs | NOK 250.00k | 0.019% NOK 15.0k | |
| Director | 9.7yrs | NOK 250.00k | no data |
9.7yrs
Average Tenure
61yo
Average Age
Experienced Board: ULTIO's board of directors are considered experienced (9.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/09 03:20 |
| End of Day Share Price | 2024/06/12 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ultimovacs ASA is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Geir Holom | DNB Markets |